Loading clinical trials...
Loading clinical trials...
A Phase 2, Open-Label, Multi-Center Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Due to Staphylococci
Conditions
Interventions
AFN-12520000
Locations
14
United States
SITE 018
Buena Park, California, United States
SITE 005
Chula Vista, California, United States
SITE 001
La Mesa, California, United States
SITE 016
Oceanside, California, United States
SITE 017
Augusta, Georgia, United States
SITE 002
Columbus, Georgia, United States
Start Date
February 1, 2012
Primary Completion Date
August 1, 2012
Completion Date
August 1, 2012
Last Updated
August 7, 2012
NCT07379684
NCT06319235
NCT07391735
NCT02060513
NCT05701475
NCT06558240
Lead Sponsor
Affinium Pharmaceuticals, Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions